The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.
Abstract
Low serum albumin levels are very common in critically ill patients, with reported incidences as high as 40-50%. This condition appears to be associated with alterations in the degree of protein binding of many highly protein-bound antibacterials, which lead to altered pharmacokinetics and pharmacodynamics, although this topic is infrequently considered in daily clinical practice. The effects of hypoalbuminaemia on pharmacokinetics are driven by the decrease in the extent of antibacterial bound to albumin, which increases the unbound fraction of the drug. Unlike the fraction bound to plasma proteins, the unbound fraction is the only fraction available for distribution and clearance from the plasma (central compartment). Hence, hypoalbuminaemia is likely to increase the apparent total volume of distribution (V(d)) and clearance (CL) of a drug, which would translate to lower antibacterial exposures that might compromise the attainment of pharmacodynamic targets, especially for time-dependent antibacterials. The effect of hypoalbuminaemia on unbound concentrations is also likely to have an important impact on pharmacodynamics, but there is very little information available on this area. The objectives of this review were to identify the original research papers that report variations in the highly protein-bound antibacterial pharmacokinetics (mainly V(d) and CL) in critically ill patients with hypoalbuminaemia and without renal failure, and subsequently to interpret the consequences for antibacterial dosing. All relevant articles that described the pharmacokinetics and/or pharmacodynamics of highly protein-bound antibacterials in critically ill patients with hypoalbuminaemia and conserved renal function were reviewed. We found that decreases in the protein binding of antibacterials in the presence of hypoalbuminaemia are frequently observed in critically ill patients. For example, the V(d) and CL of ceftriaxone (85-95% protein binding) in hypoalbuminaemic critically ill patients were increased 2-fold. A similar phenomenon was reported with ertapenem (85-95% protein binding), which led to failure to attain pharmacodynamic targets (40% time for which the concentration of unbound [free] antibacterial was maintained above the minimal inhibitory concentration [fT>MIC] of the bacteria throughout the dosing interval). The V(d) and CL of other highly protein-bound antibacterials such as teicoplanin, aztreonam, fusidic acid or daptomycin among others were significantly increased in critically ill patients with hypoalbuminaemia compared with healthy subjects. Increased antibacterial V(d) appeared to be the most significant pharmacokinetic effect of decreased albumin binding, together with increased CL. These pharmacokinetic changes may result in decreased achievement of pharmacodynamic targets especially for time-dependent antibacterials, resulting in sub-optimal treatment. The effects on concentration-dependent antibacterial pharmacodynamics are more controversial due to the lack of data on this topic. In conclusion, altered antibacterial-albumin binding in the presence of hypoalbuminaemia is likely to produce significant variations in the pharmacokinetics of many highly protein-bound antibacterials. Dose adjustments of these antibacterials in critically ill patients with hypoalbuminaemia should be regarded as another step for antibacterial dosing optimization. Moreover, some of the new antibacterials in development exhibit a high level of protein binding although hypoalbuminaemia is rarely considered in clinical trials in critically ill patients. Further research that defines dosing regimens that account for such altered pharmacokinetics is recommended.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“patients with febrile neutropenia who fail to defervesce after 4-7 days of broad-spectrum antibacterial therapy are at increased risk of having fungal disease (Table 2) (175, 176).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [175]
In the citing paper
“Augmented renal clearance [240], AKI [241], hypoalbuminemia [242], RRT [243, 244], and extracorporeal membrane oxygenation [245, 246] are examples of common scenarios that affect the concentrations of some antibiotics.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [242]
Citations
Cites
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109 · cited 1×
“This is of particular relevance for critically ill patients where early and appropriate therapy is a cornerstone in the treatment of severe infections.([22,23]) After the drug distribution phase, the drug elimination phase is driven by drug clearance from the intravascular compartment.”
BackgroundCraig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908 · cited 4×
“Penicillins, cephalosporins and monobactams belong to the b-lactam family of antibacterials and are categorized as ‘timedependent’ antibacterials, where antibacterial activity is related to the ƒT>MIC.([50]) Penicillins and monobactams are reported to require at least 50–60% ƒT>MIC for maximal bactericidal activity, w…”
BackgroundInfluentialTHE PHENOMENON OF THE ACUTE PHASE RESPONSE*
Kushner, I. (1982) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1982.tb22124.x · Cited by 1,479 · cited 1×
“Moreover, as a negative acute-phase reactant, albumin has its hepatic synthesis downregulated in patients that present with a stress response, which is also commonly observed in critically ill patients.([14]) Malnutrition is another common cause of hypoalbuminaemia.”
BackgroundAntimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930 · cited 1×
“Although belonging to the b-lactam family of antibacterials, carbapenems are often considered as a separate class because of a lower ƒT>MIC requirement (40%) for maximal bacterial killing activity.([55]) Ertapenem is highly albumin bound (85–95%), which considerably extends its elimination half-life (t1⁄2; 4.”
BackgroundINCREASED VASCULAR PERMEABILITY: A MAJOR CAUSE OF HYPOALBUMINAEMIA IN DISEASE AND INJURY
Fleck, A., Hawker, F., Wallace, P. I., Raines, G., Trotter, J., Ledingham, I. M., & Calman, K. C. (1985) · The Lancet · doi:10.1016/s0140-6736(85)91447-3 · Cited by 898 · cited 2×
“Fleck et al.[12] showed a 200% increased rate of transcapillary escape of albumin from intravascular to extravascular space during the first 2 days of admission in critically ill patients with shock and a mean serum albumin concentration of 25 g/L.”
BackgroundPharmacokinetic issues for antibiotics in the critically ill patient
Roberts, J. A., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181961bff · Cited by 862 · cited 6×
“Although these pharmacokinetics cannot be extrapolated to critically ill patients thatmayalsohave physiologically enhancedVd and CL,[2] the data are instructive for describing the effect of hypoalbuminaemia, in the absence of other pathology, on the pharmacokinetics of highly protein-bound antibacterials.”
BackgroundSelf-citationThe Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia
RELLO, J., GALLEGO, M., MARISCAL, D., SOÑORA, R., & VALLES, J. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.156.1.9607030 · Cited by 467 · cited 1×
“This is of particular relevance for critically ill patients where early and appropriate therapy is a cornerstone in the treatment of severe infections.([22,23]) After the drug distribution phase, the drug elimination phase is driven by drug clearance from the intravascular compartment.”
BackgroundSelf-citationThe treatment of Wilms' tumor. Results of the national Wilms' tumor study
D'Angio, G. J., Evans, A. E., Breslow, N., Beckwith, B., Bishop, H., Feigl, P., Goodwin, W., Leape, L. L., Sinks, L. F., Sutow, W., et al. (1976) · Cancer · doi:10.1002/1097-0142(197608)38:2<633::aid-cncr2820380203>3.0.co;2-s · Cited by 457
Augmented Renal Clearance: Implications for Antibacterial Dosing in the Critically Ill
Udy, A. A., Roberts, J. A., Boots, R. J., Paterson, D. L., & Lipman, J. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318140-000000000-00000 · Cited by 377
Self-citationDvorchik, B. H., Brazier, D., DeBruin, M. F., & Arbeit, R. D. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1318-1323.2003 · Cited by 358 · cited 2×
“The authors compared data from burns patients with data from healthy subjects([46]) and noted Cmax and AUC24 values in the burns patients that were nearly half those observed in the healthy subjects.”
Result
Research works printed but not linked: 4
- Craig, 1978, Scand J Infect Dis Suppl, &NA;, 239
- Friend, 1997, Adv Perit Dial, 13, 155
- Goldstein, 1949, J Pharmacol Exp Ther, 95, 102
- Van Dalen, 1987, Pharm Weekbl Sci, 9, 98
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Self-citationSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Self-citationRoberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., Hope, W. W., Farkas, A., Neely, M. N., Schentag, J. J., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70036-2 · Cited by 1,046
Self-citationGuilhaumou, R., Benaboud, S., Bennis, Y., Dahyot-Fizelier, C., Dailly, E., Gandia, P., Goutelle, S., Lefeuvre, S., Mongardon, N., Roger, C., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2378-9 · Cited by 543
Hypoalbuminemia as Surrogate and Culprit of Infections
Wiedermann, C. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094496 · Cited by 394
“Ceftriaxone is a ß-lactam antibiotic with extensive protein binding of 85% to 95% [190,191].”
Background
Metadata
- Authors
- Ulldemolins, M., Roberts, J. A., Rello, J., Paterson, D. L., & Lipman, J.
- Affiliations
- The University of Queensland (AU)
- Universitat Autònoma de Barcelona (ES)
- Corresponding author
- Roberts, Jason A.
- Venue
- Clinical Pharmacokinetics
- Published
- 2011-02
- Volume
- 50
- Issue
- 2
- Pages
- 99-110
- ISSN
- 0312-5963 (ISSN-L)
- OpenAlex
- W1982910325
- Cited by
- 469
- References
- 60
- Citations by year
- 2026: 32 · 2025: 44 · 2024: 38 · 2023: 40 · 2022: 47 · 2021: 39 · 2020: 44 · 2019: 26 · 2018: 17 · 2017: 24 · 2016: 23 · 2015: 28 · 2014: 21 · 2013: 15 · 2012: 23
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacokinetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Queensland Health
- Australian and New Zealand College of Anaesthetists
- Medical Research Council
- National Health and Medical Research Council (519702)
- Agència de Gestió d'Ajuts Universitaris i de Recerca
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Interaction Studies and Fluorescence Analysis
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- hypoalbuminemia, critically ill patients, protein binding, drug-albumin binding, unbound drug fraction, volume of distribution, drug clearance, pharmacokinetics, pharmacodynamics, time above MIC, ceftriaxone, ertapenem, teicoplanin, aztreonam, fusidic acid, daptomycin
- MeSH terms
- Anti-Bacterial Agents, Clinical Trials as Topic, Humans, Kidney Function Tests, Microbial Sensitivity Tests, Protein Binding, Critical Illness, Hypoalbuminemia, Drug Dosage Calculations
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. https://app.cochat.ai/papers/10.2165/11539220-000000000-00000
- The paper
- Ulldemolins, M., Roberts, J. A., Rello, J., Paterson, D. L., & Lipman, J. (2011). The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clinical Pharmacokinetics. https://doi.org/10.2165/11539220-000000000-00000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.